Chimeric antigen receptor-engineered T cells for cancer immunotherapy: Progress and challenges

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Han, Ethan Q ^a   Li, Xiu Ling ^b   Wang, Chun Rong ^b   Li, Tian Fang ^c   Han, Shuang Yin ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; Single chain variable fragment; T cell receptor

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHIMERIC T LYMPHOCYTE ANTIGEN RECEPTOR; CYCLOPHOSPHAMIDE; EPITOPE; FLUDARABINE; INTERLEUKIN 15; INTERLEUKIN 2; LENTIVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR ENGINEERED T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DNA MODIFICATION; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRACELLULAR SIGNALING; LOW ENERGY RADIATION; LYMPHOBLASTOID CELL LINE; LYMPHOMA; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; STABLE EXPRESSION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TRANSIENT EXPRESSION; TUMOR MICROENVIRONMENT; WHOLE BODY RADIATION; ANIMAL; GENETICS; IMMUNOLOGY; METHODOLOGY; NEOPLASM; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84879813079     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-47     Document Type: Review

References (52)

1. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Eshhar Z, Waks T, Gross G, Schindler DG, Proc Natl Acad Sci USA 1993 90 2 720 724 10.1073/pnas.90.2.720 8421711 (Pubitemid 23028937)
2. Chimeric antigen receptors for T-cell based therapy. Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, et al. Methods Mol Biol 2012 907 645 666 22907378
3. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Kochenderfer JN, Rosenberg SA, Nat Rev Clin Oncol 2013 10 5 267 276 10.1038/nrclinonc.2013.46 23546520
4. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. Porter DL, Levine BL, Kalos M, Bagg A, June CH, N Engl J Med 2011 365 8 725 733 10.1056/NEJMoa1103849 21830940
5. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. Sci Transl Med 2013 5 177 177ra38 10.1126/scitranslmed. 3005930 23515080
6. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. N Engl J Med 2013 368 16 1509 1518 10.1056/NEJMoa1215134 23527958
7. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Xu XJ, Zhao HZ, Tang YM, Leuk Lymphoma 2013 54 2 255 260 10.3109/10428194.2012.715350 22897728
8. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, et al. Blood 2013 121 7 1165 1174 10.1182/blood-2012-06-438002 23243285
9. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, et al. Mol Ther 2007 15 4 825 833 17299405 (Pubitemid 46432004)
10. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Blood 2011 118 23 6050 6056 10.1182/blood-2011-05-354449 21984804
11. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Mol Ther 2013 21 4 904 912 10.1038/mt.2013.17 23423337
12. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA, Mol Ther 2010 18 4 843 851 10.1038/mt.2010.24 20179677
13. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Kandalaft LE, Powell DJ Jr, Coukos G, J Transl Med 2012 10 157 10.1186/1479-5876-10-157 22863016
14. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG, Clin Dev Immunol 2012 201 2 238924
15. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, et al. Hum Gene Ther 2012 23 10 1043 1053 10.1089/hum.2012.041 22780919
16. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M, Nat Biotechnol 2013 31 1 71 75 23242161
17. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Shirasu N, Kuroki M, Anticancer Res 2012 32 6 2377 2383 22641678
18. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR, Clin Cancer Res 2013 19 12 3153 3164 10.1158/1078-0432.CCR-13-0330 23620405
19. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA, Cancer Res 2013 73 11 3371 3380 10.1158/0008-5472.CAN-12-3913 23633494
20. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Zhang T, Barber A, Sentman CL, Cancer Res 2007 67 22 11029 11036 10.1158/0008-5472.CAN-07-2251 18006849 (Pubitemid 350145933)
21. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc spacer domain in the extracellular moiety of chimeric antigen receptors avoids off-target activation and unintended initiation of an innate immune response. Hombach A, Hombach AA, Abken H, Gene Ther 2010 17 10 1206 1213 10.1038/gt.2010.91 20555360
22. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al. J Immunother 2005 28 3 203 211 10.1097/01.cji.0000161397.96582.59 15838376 (Pubitemid 40593985)
23. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE, J Immunol 2010 184 12 6938 6949 10.4049/jimmunol.0901766 20483753
24. CD28 Costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, et al. J Clin Invest 2011 121 5 1822 1826 10.1172/JCI46110 21540550
25. 4-1BB And CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X, Hum Gene Ther 2010 21 1 75 86 10.1089/hum.2009.122 19719389
26. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. Finney HM, Akbar AN, Lawson AD, J Immunol 2004 172 1 104 113 14688315 (Pubitemid 38020461)
27. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, et al. Mol Ther 2009 17 8 1453 1464 10.1038/mt.2009.83 19384291
28. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, et al. J Hematol Oncol 2013 6 33 10.1186/1756-8722-6-33 23656794
29. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? Klebanoff CA, Gattinoni L, Restifo NP, J Immunother 2012 35 9 651 660 10.1097/CJI.0b013e31827806e6 23090074
30. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR, J Clin Invest 2008 118 1 294 305 10.1172/JCI32103 18060041
31. A human memory T cell subset with stem cell-like properties. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. Nat Med 2011 17 10 1290 1297 10.1038/nm.2446 21926977
32. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, Aguilar B, Ostberg JR, Riddell SR, Forman SJ, et al. J Immunother 2012 35 9 689 701 10.1097/CJI.0b013e318270dec7 23090078
33. Artificial antigen-presenting cells for use in adoptive immunotherapy. Turtle CJ, Riddell SR, Cancer J 2010 16 4 374 381 10.1097/PPO.0b013e3181eb33a6 20693850
34. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Klebanoff CA, Tagaya Y, et al. J Immunol 2006 176 9 5255 5266 16621991
35. IL-15 enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and CD8+ effector-memory T cells. Mueller YM, Makar V, Bojczuk PM, Witek J, Katsikis PD, Int Immunol 2003 15 1 49 58 10.1093/intimm/dxg013 12502725 (Pubitemid 36163768)
36. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and eomesodermin. Rao RR, Li Q, Odunsi K, Shrikant PA, Immunity 2010 32 1 67 78 10.1016/j.immuni.2009. 10.010 20060330
37. Safety and stability of retrovirally transduced chimeric antigen receptor T cells. Colovos C, Villena-Vargas J, Adusumilli PS, Immunotherapy 2012 4 9 899 902 10.2217/imt.12.91 23046233
38. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, et al. Sci Transl Med 2012 4 132 132ra53 10.1126/scitranslmed.3003761 22553251
39. Patient monitoring and follow-up in lentiviral clinical trials. McGarrity GJ, Hoyah G, Winemiller A, Andre K, Stein D, Blick G, Greenberg RN, Kinder C, Zolopa A, Binder-Scholl G, et al. J Gene Med 2013 15 2 78 82 10.1002/jgm.2691 23322669
40. Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Schroers R, Hildebrandt Y, Hasenkamp J, Glass B, Lieber A, Wulf G, Piesche M, Exp Hematol 2004 32 6 536 546 10.1016/j.exphem.2004.03.010 15183894 (Pubitemid 38739465)
41. Sleeping beauty system to redirect T-cell specificity for human applications. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, et al. J Immunother 2013 36 2 112 123 10.1097/CJI.0b013e3182811ce9 23377665
42. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM, Mol Ther 2011 19 12 2133 2143 10.1038/mt.2011.131 21772253
43. Treatment of advanced leukemia in mice with mRNA engineered T cells. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA, Hum Gene Ther 2011 22 12 1575 1586 10.1089/hum.2011.070 21838572
44. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. J Clin Oncol 2008 26 32 5233 5239 10.1200/JCO.2008.16.5449 18809613
45. Durable complete responses in heavily pretreted patients with metastatic melanoma using T cell transfer immunotherapy. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Clin Cancer Res 2011 17 13 4550 4557 10.1158/1078-0432.CCR-11-0116 21498393
46. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH, Sci Transl Med 2011 3 95 95ra73 10.1126/scitranslmed.3002842 21832238
47. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Nature Med 2004 10 9 942 949 10.1038/nm1093 15322536 (Pubitemid 39273735)
48. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumour-specific CD8+ T cells. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, et al. J Exp Med 2005 202 7 907 912 10.1084/jem.20050732 16203864 (Pubitemid 41396891)
49. Dendritic cells acquire the MAGE-3 human tumour antigen from apoptotic cells and induce a class I-restricted T cell response. Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, Villa A, Bordignon C, Traversari C, Proc Natl Acad Sci USA 2000 97 5 2185 2190 10.1073/pnas.040540197 10681453 (Pubitemid 30134043)
50. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M, Mol Ther 2010 18 4 666 668 10.1038/mt.2010.31 20357779
51. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric- antigen -receptor-transduced T cells. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al. Blood 2012 119 12 2709 2720 10.1182/blood-2011-10-384388 22160384
52. Inducible apoptosis as a safety switch for adoptive cell therapy. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. N Engl J Med 2011 365 18 1673 1683 10.1056/NEJMoa1106152 22047558